Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial

被引：0

作者：

Siegel, David Samuel DiCapua

Richardson, Paul Gerard Guy

Vij, Ravi

Hofmeister, Craig C.

Baz, Rachid C.

Jagannath, Sundar

Chen, Christine

Lonial, Sagar

Jakubowiak, Andrzej J.

Bahlis, Nizar J.

Song, Kevin W.

Belch, Andrew

Raje, Noopur S.

Shustik, Chaim

Lentzsch, Suzanne

Chen, Min

Zaki, Mohamed H.

Anderson, Kenneth Carl

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Washington Univ, St Louis, MO USA

[4] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA

[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[6] Mt Sinai Med Ctr, New York, NY 10029 USA

[7] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[8] Emory Univ, Sch Med, Atlanta, GA USA

[9] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[10] Univ Calgary, Calgary, AB, Canada

[11] Vancouver Gen Hosp, Vancouver, BC, Canada

[12] Univ Alberta, Edmonton, AB, Canada

[13] Massachusetts Gen Hosp, Boston, MA 02114 USA

[14] McGill Univ, Royal Victoria Hosp, Ctr Hlth, Montreal, PQ H3A 1A1, Canada

[15] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA

[16] Celgene Corp, Summit, NJ USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8588

引用

页数：1

共 50 条

[1] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis
Jagannath, Sundar
Hofmeister, Craig C.
Baz, Rachid C.
Siegel, David Samuel DiCapua
Vij, Ravi
Chen, Christine
Lonial, Sagar
Anderson, Kenneth Carl
Chen, Min
Zaki, Mohamed H.
Richardson, Paul Gerard Guy
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] SAFETY AND EFFICACY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: LONG-TERM FOLLOW-UP OF PATIENTS ENROLLED IN THE MM-002 PHASE 2 TRIAL
Richardson, P.
Siegel, D.
Vij, R.
Hofmeister, C.
Baz, R.
Jagannath, S.
Chen, C.
Lonial, S.
Jakubowiak, A.
Bahlis, N.
Song, K.
Belch, A.
Raje, N.
Shustik, C.
Lentzsch, S.
Chen, M.
Zaki, M.
Anderson, K.
HAEMATOLOGICA, 2013, 98 : 321 - 321
[3] THE EFFICACY AND SAFETY OF POMALIDOMIDE WITH OR WITHOUT LOW-DOSE DEXAMETHASONE IS NOT IMPACTED BY AGE IN PATIENTS WITH ADVANCED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: MM-002 SUBGROUP ANALYSIS
Jagannath, S.
Hofmeister, C.
Baz, R.
Siegel, David S.
Vij, R.
Chen, C.
Lonial, S.
Anderson, K.
Chen, M.
Zaki, M.
Richardson, P.
HAEMATOLOGICA, 2013, 98 : 325 - 326
[4] Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)
Cavo, Michele
Corradini, Paolo
Di Raimondo, Francesco
Petrini, Mario
Cafro, Anna Maria
di Toritto, Tommaso Caravita
Offidani, Massimo
Semenzato, Gianpietro
Zambello, Renato
Lazzaro, Antonio
Petrucci, Maria Teresa
Rodeghiero, Francesco
Simcock, Mathew
Slaughter, Ana
Herring, Jennifer
Peluso, Teresa
Palumbo, Antonio
BLOOD, 2015, 126 (23)
[5] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Weisel, Katja C.
Ocio, Enrique M.
Di Raimondo, Francesco
Hansson, Markus
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2015, 126 (23)
[6] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes
Siegel, David S.
Richardson, Paul G.
Baz, Rachid
Chen, Min
Zaki, Mohamed
Anderson, Kenneth C.
BLOOD, 2012, 120 (21)
[7] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
Vij, Ravi
Hofmeister, Craig C.
Richardson, Paul G.
Jagannath, Sundar
Siegel, David S.
Baz, Rachid
Chen, Min
Zaki, Mohamed
Larkins, Gail
Anderson, Kenneth C.
BLOOD, 2012, 120 (21)
[8] MM-007: A phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM).
Richardson, Paul G.
Bensmaine, Amine
Doerr, Thomas
Wang, Jianming
Zaki, Mohamed H.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Hudgens, Stacie
Yu, Zhinuan
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
San-Miguel, Jesus F.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[10] Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).
Vij, Ravi
Richardson, Paul Gerard Guy
Jagannath, Sundar
Siegel, David Samuel DiCapua
Baz, Rachid C.
Srinivasan, Shankar
Larkins, Gail
Zaki, Mohamed H.
Hussein, Mohamad A.
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →